Tirzepatide is oral only, sold as a three-month supply at $1,047, or $891 paid in full, with no month-to-month rate
By fostering a patient-centered environment, they ensure that each individual receives personalized care tailored to their unique health needs
Browne AJ, Kashef Hamadani BH, Kumaran EAP, Rao P, Longbottom J, Harriss E, Moore CE, Dunachie S, Basnyat B, Baker S, Lopez AD, Day NPJ, Hay SI, Dolecek C (2020) Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis
This agrees with a study conducted by Farahatet and colleagues, and Moin and colleagues who stated that skin types III-IV is a risk factor with negative therapeutic outcome in melasma treatment